Chiome Bioscience (TSE:4583) Total Liabilities: 円605.4 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4583 Chiome Bioscience Inc TSE:4583
38 GF Score
Price 円69.00
GF Value 円106.02
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is Chiome Bioscience Total Liabilities?

Chiome Bioscience TSE:4583 -1.43% 38 Total Liabilities is 円605.4 Mil as of Dec. 2025. GuruFocus rates TSE:4583 with a GF Score™ of 38/100 and a GF Value™ of 円106.02 (Possible Value Trap). The stock has 1 warning sign investors should review.

Chiome Bioscience's Total Liabilities for the quarter that ended in Dec. 2025 was 円605.4 Mil.

Chiome Bioscience's quarterly Total Liabilities declined from Jun. 2025 (円443.40 Mil) to Sep. 2025 (円299.30 Mil) but then increased from Sep. 2025 (円299.30 Mil) to Dec. 2025 (円605.44 Mil).

Chiome Bioscience's annual Total Liabilities declined from Dec. 2023 (円593.73 Mil) to Dec. 2024 (円548.55 Mil) but then increased from Dec. 2024 (円548.55 Mil) to Dec. 2025 (円605.44 Mil).

Chiome Bioscience Total Liabilities Historical Data

* Premium members only.

The historical data trend for Chiome Bioscience's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chiome Bioscience Total Liabilities Chart

Chiome Bioscience Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 446.39 424.72 593.73 548.55 605.44

Chiome Bioscience Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 443.44 443.40 299.30 605.44 358.22
TSE:4583
38GF Score
Chiome Bioscience Inc TSE:4583
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chiome Bioscience Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Chiome Bioscience's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=374.885+(175+55.555
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=605.4

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=1727.504-1122.064
=605.4

Chiome Bioscience's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=374.885+(175+55.555
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=605.4

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=1727.504-1122.064
=605.4

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of 円605.4 Mil mean?
Chiome Bioscience (TSE:4583) has a Total Liabilities of 円605.4 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Chiome Bioscience and its competitors.
Is Chiome Bioscience's Total Liabilities too high?
Chiome Bioscience's current Total Liabilities is 円605.4 Mil. Overall, Chiome Bioscience has a GF Score™ of 38/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Chiome Bioscience's Total Liabilities compare to VRTX and REGN?
Chiome Bioscience's Total Liabilities of 円605.4 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Chiome Bioscience and its competitors. Chiome Bioscience's current Total Liabilities is 円605.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chiome Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Chiome Bioscience (TSE:4583) is currently considered Possible Value Trap. The stock's GF Value™ is 円106.02, compared to a current price of 円69.00 — trading 34.9% below its estimated fair value. The current Total Liabilities is 円605.4 Mil. Chiome Bioscience's overall GF Score™ is 38/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Chiome Bioscience (TSE:4583), the current Total Liabilities is 円605.4 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chiome Bioscience (TSE:4583) Overvalued in 2026?

Based on GuruFocus' analysis, Chiome Bioscience stock appears to be undervalued. The current stock price of 円69.00 is trading 34.9% below its estimated GF Value™ of 円106.02. GuruFocus considers Chiome Bioscience to be Possible Value Trap.

Key valuation signals for TSE:4583:

  • Total Liabilities: 円605.4 Mil
  • GF Value™: 円106.02 vs. price of 円69.00 (34.9% below fair value)
  • GF Score™: 38/100 with 1 warning sign

No single metric tells the full story. See the TSE:4583 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Chiome Bioscience Business Description

Address 3-12-1 Honmachi, No. 6, Sumitomo Fudosan Nishi Shinjuku Building, Shibuya-ku, Tokyo, JPN, 151-0071
Chiome Bioscience Inc is engaged in the discovery and development of antibody drugs, focusing on early-stage research and initial clinical trials. The company operates through two reportable segments: the Drug Discovery segment and the Drug Discovery Support segment. The Drug Discovery segment conducts research on antibody creation for diseases with high unmet medical needs and aims to generate revenue through licensing agreements, upfront payments, milestone payments, and royalties. The Drug Discovery Support segment provides services such as antibody production and related support using proprietary antibody technologies, catering to pharmaceutical and diagnostic companies as well as academic institutions.
38GF Score

Get the complete analysis for TSE:4583

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円69.00
Price
円106.02
GF Value